Showing 3251-3260 of 3437 results for "".
- CryoShape Uses Cold to Reduce Scarshttps://practicaldermatology.com/news/20121203-cryoshape_uses_cold_to_reduce_scars/2459667/CryoShape is a patented handheld device for treating keloid and hypertrophic scars. Physicians can destroy deep tissue using an extremely cold probe that is injected directly into the scar. Treating scars with cold freezes them from the inside,
- Grants Awarded from National Rosacea Societyhttps://practicaldermatology.com/news/20121127-grants_awarded_from_national_rosacea_society/2459673/The National Rosacea Society (NRS) awarded funding to five new studies as part of its research grants program to increase knowledge and understanding of rosacea. Dr. Anna Di Nardo, associate professor of medicine at the University of California-San Diego, received $25,000 to study the role of mast c
- Picato Approved in European Unionhttps://practicaldermatology.com/news/20121119-picato_approved_in_european_union/2459677/The European Commission has granted marketing authorization for LEO Pharma's Picato (ingenol mebutate) gel for the treatment of actinic keratosis in the European Union (EU). Picato was approved in the US earlier this year.
- ADCS Acquires More Clinicshttps://practicaldermatology.com/news/20121106-adcs_acquires_more_clinics/2459683/After announcing a major acquisition of multiple clinics on Florida's West Coast, Advanced Dermatology & Cosmetic Surgery (ADCS) has acquired two clinics in the Florida Keys from the practice of Dr. Karen Weismantle. The clinics are
- Janssen to Develop, Commercialize JAK Inhibitor For Immunological Diseaseshttps://practicaldermatology.com/news/20121002-janssen_to_develop_commercialize_jak_inhibitor_for_immunological_diseases/2459720/Janssen Biotech, Inc. entered into a license agreement with Astellas Pharma Inc. for the worldwide development and commercialization, except in Japan, of ASP015K, an oral, small molecule Janus Kinase (JAK) inhibitor. ASP015K is currently in Phase 2b development as a once-daily oral treatment for mod
- p53R2 Regulates Proliferation and Chemosensitivity in Melanomahttps://practicaldermatology.com/news/20120918-p53r2_regulates_proliferation_and_chemosensitivity_in_melanoma/2459734/Expression of p53R2 significantly correlates with the depth of invasion and the tumor stage in melanoma, new research shows. (J Dermatol Sci; 68(1):19-24) Furthermore, use of siRNA targeting p53R2 successfully knocked down p53R2 and significantly inhibited the growth of KHm5 and 6 cells. The degree
- Study: HA Fillers Effective for Full-face Rejuvenationhttps://practicaldermatology.com/news/20120824-study_ha_fillers_effective_for_full-face_rejuvenation/2459747/In subjects with multiple indications, full-face rejuvenation using hyaluronic acid (HA) fillers” provided effective, safe, and satisfactory results,” one of the first studies of its kind concludes. (Dermatol Surg;38(7 Pt 2):1153-61) The six-month study involved 77 subjects treated with five differe
- HHS Announces Next Steps To Promote Use Of Electronic Health Recordshttps://practicaldermatology.com/news/20120823-hhs_announces_next_steps_to_promote_use_of_electronic_health_records/2459749/Health and Human Services (HHS) Secretary Kathleen Sebelius
- Suneva Medical Launches ReGenica Skincarehttps://practicaldermatology.com/news/20120809-suneva_medical_launches_regenica_skincare/2459753/Suneva Medical launched ReGenica Skincare, a three-product rejuvenation system, that contains a variety of proteins and growth factors in a serum-free solution known as Multipotent CCM Complex, says the company. In one study, ReGenica Advanced Re
- Zein Obagi, MD To Direct 24th Ultimate Skin Health Symposiumhttps://practicaldermatology.com/news/20120807-zein_obagi_md_to_direct_24th_ultimate_skin_health_symposium/2459755/Zein E. Obagi, MD was named director of the 24th Ultimate Skin Health Symposium, a three-day skin rejuvenation program taking place at the Montage Hotel, Beverly Hills, CA, from November 9-11, 2012. Key topics of the symposium will i